Breaking down barriers: The potential of smarter CAR‐engineered NK cells against solid tumors

Natural killer (NK) cells are considered to be the foremost fighters of our innate immune system against foreign invaders and thus tend to promptly latch onto the virus‐infected and tumor/cancerous cells, killing them through phagocytosis. At present, the application of genetically engineered Chimer...

Full description

Saved in:
Bibliographic Details
Published inJournal of cellular biochemistry Vol. 124; no. 8; pp. 1082 - 1104
Main Authors Khawar, Muhammad B., Gao, Guangzhong, Rafiq, Mussarat, Shehzadi, Anila, Afzal, Ali, Abbasi, Muddasir H., Sheikh, Nadeem, Afzal, Nimra, Ashraf, Muhammad A., Hamid, Syeda E., Shahzaman, Sara, Kawish, Naseer, Sun, Haibo
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.08.2023
Subjects
Antigens
CAR‐NK cell immunotherapy
Chimeric antigen receptors
Clinical trials
Genetic engineering
Immune system
Immunotherapy
Innate immunity
Natural killer cells
Phagocytosis
preclinical and clinical studies
preference over CAR‐T immunotherapy
Receptors
Solid tumors
Tumor cells
Tumors
Viruses
preclinical and clinical studies
CAR-NK cell immunotherapy
preference over CAR-T immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Natural killer (NK) cells are considered to be the foremost fighters of our innate immune system against foreign invaders and thus tend to promptly latch onto the virus‐infected and tumor/cancerous cells, killing them through phagocytosis. At present, the application of genetically engineered Chimeric antigen receptor (CAR) receptors ensures a guaranteed optimistic response with NK cells and would not allow the affected cells to dodge or escape unchecked. Hence the specificity and uniqueness of CAR‐NK cells over CAR‐T therapy make them a better immunotherapeutic choice to reduce the load of trafficking of numerous tumor cells near the healthy cell populations in a more intact way than offered by CAR‐T immunotherapy. Our review mainly focuses on the preclinical, clinical, and recent advances in clinical research trials and further strategies to achieve an augmented and efficient cure against solid tumors.
Bibliography:Muhammad B. Khawar, Guangzhong Gao, Mussarat Rafiq, Anila Shehzadi, and Ali Afzal contributed equally to this work.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0730-2312
1097-4644
DOI:10.1002/jcb.30460